Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Real-world study determining the safety and efficacy of teclistamab in R/R multiple myeloma

Shonali Midha, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a real-world study determining the safety and efficacy of teclistamab, a BCMA-targeting bispecific antibody, in the treatment of patients with relapsed/refractory (R/R) multiple myeloma. Dr Midha compares the findings of this real-world study with results from the MajesTEC-1 trial (NCT04557098). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Pfizer, AbbVie